Innere Medizin (Heidelberg, Germany)最新文献

[Treatment of type 2 diabetes mellitus]. 2型糖尿病的治疗

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-19 DOI: 10.1007/s00108-026-02171-9

Reiner Jumpertz von Schwartzenberg, Julia Király

引用次数: 0

[Invasive intracoronary imaging : Role in routine cardiology]. [有创冠状动脉内成像：在常规心脏病学中的作用]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-15 DOI: 10.1007/s00108-026-02190-6

Denitsa Meteva, Youssef S Abdelwahed, Ulf Landmesser

引用次数: 0

[Infection with Orientia tsutsugamushi and hospital-acquired pneumonia]. [恙虫病东方体感染与医院获得性肺炎]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-09 DOI: 10.1007/s00108-026-02185-3

Ilka Grewe, Saskia Winzer, Silja Steinmann, Paul Francke, Aiman Gamal Abdelrahim, Annette Hennigs, Marylyn M Addo, Michael Ramharter, Dominic Wichmann, Stefan Schmiedel

{"title":"[Infection with Orientia tsutsugamushi and hospital-acquired pneumonia].","authors":"Ilka Grewe, Saskia Winzer, Silja Steinmann, Paul Francke, Aiman Gamal Abdelrahim, Annette Hennigs, Marylyn M Addo, Michael Ramharter, Dominic Wichmann, Stefan Schmiedel","doi":"10.1007/s00108-026-02185-3","DOIUrl":"https://doi.org/10.1007/s00108-026-02185-3","url":null,"abstract":"Background: Tsutsugamushi fever is an infection caused by Orientia tsutsugamushi that is rarely diagnosed in Europe but endemic in several Asian countries and in Chile. Its clinical presentation is often nonspecific, ranging from fever, myalgia, lymphadenopathy, and a maculopapular rash to severe disease with multiorgan involvement.Case report: A 34-year-old man presented with fever, myalgia, lymphadenopathy, and a maculopapular rash after returning from Thailand. Despite empiric antimicrobial therapy, his condition deteriorated rapidly, with respiratory failure, impaired consciousness, and hypotension. Polymerase chain reaction (PCR) testing of peripheral blood confirmed O. tsutsugamushi. Treatment with doxycycline, along with meropenem for hospital-acquired pneumonia, resulted in rapid clinical improvement.Conclusion: This case highlights the importance of considering tsutsugamushi fever in febrile travelers returning from endemic regions. Timely presumptive or PCR-based diagnosis and initiation of effective therapy are crucial to prevent severe disease with multiorgan involvement and secondary complications.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Personalized drug therapy of metastatic lung cancer]. 【转移性肺癌个体化药物治疗】。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-06 DOI: 10.1007/s00108-026-02150-0

Sofia Stilianakis, Lea Ruge, Heather Scharpenseel, Malte Verheyen, Jürgen Wolf

{"title":"[Personalized drug therapy of metastatic lung cancer].","authors":"Sofia Stilianakis, Lea Ruge, Heather Scharpenseel, Malte Verheyen, Jürgen Wolf","doi":"10.1007/s00108-026-02150-0","DOIUrl":"https://doi.org/10.1007/s00108-026-02150-0","url":null,"abstract":"In precision oncology, therapies are tailored to the tumor's individual molecular and immunological characteristics in order to maximize efficacy while minimizing side effects. This approach has recently led to a significant expansion of treatment options, particularly for non-small cell lung cancer (NSCLC). Traditionally, this refers to receptor inhibitors-mostly tyrosine kinase inhibitors-that inhibit receptors on the cell surface activated by oncogenic alterations (e.g., mutations, fusions). More recent approaches also include bispecific antibodies, antibody-drug conjugates (ADCs), and, in a broader sense, the selection of immunotherapies for specific molecular subgroups. Comprehensive immunohistochemical and molecular diagnostics are therefore crucial for selecting the optimal and personalized treatment strategy-both at initial diagnosis and following disease progression. Furthermore, new prospects are currently emerging in the treatment of small cell lung cancer (SCLC) through the development of bispecific T‑cell engagers. This article aims to provide an overview of the latest targeted treatment options for lung cancer, with a particular focus on NSCLC.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The Nephrogeriatrics Research Network-achieving more through interdisciplinary approaches]. [肾脏老年病学研究网络——通过跨学科方法取得更多成就]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-05 DOI: 10.1007/s00108-026-02195-1

Maximilian König, Anna Maria Affeldt, Lena Schulte-Kemna, Susanne Fleig, Anastasia Paulmann, Hristos Karakizlis, Polina Todorova, Lukas Eberwein, Elke Schäffner, Clemens Grupp, Sarah-Yasmin Thomsen, Ute Hoffmann

{"title":"[The Nephrogeriatrics Research Network-achieving more through interdisciplinary approaches].","authors":"Maximilian König, Anna Maria Affeldt, Lena Schulte-Kemna, Susanne Fleig, Anastasia Paulmann, Hristos Karakizlis, Polina Todorova, Lukas Eberwein, Elke Schäffner, Clemens Grupp, Sarah-Yasmin Thomsen, Ute Hoffmann","doi":"10.1007/s00108-026-02195-1","DOIUrl":"https://doi.org/10.1007/s00108-026-02195-1","url":null,"abstract":"The interface between nephrology and geriatrics is becoming increasingly important. As the population ages, chronic kidney disease (CKD) in older adults is increasingly important. The physiological decline in renal function, combined with the high burden of comorbidities in older people, contributes substantially to the high prevalence of CKD in later life and to the increasing number of affected individuals. Reduced kidney function is closely associated with multimorbidity, polypharmacy, functional decline, cognitive impairment, and frailty.The specialties geriatrics and nephrology both focus on holistic, complex-care, in which multimorbidity management, individualized treatment planning, and the preservation of functional independence are central goals. Despite this conceptual overlap, an integrated nephrogeriatric perspective has not been adequately incorporated into research and clinical care.Against this background, the Nephrogeriatrics Research Network was established in 2024. As an open, interdisciplinary network, it promotes collaboration among researchers working at the intersection of nephrology and geriatrics, brings together clinical and methodological expertise, and-in close affiliation with DGG (Deutsche Gesellschaft für Geriatrie) and DGfN (Deutsche Gesellschaft für Nephrologie)-enhances the visibility of the field. The goals are to strengthen the evidence base for older, multimorbid individuals with CKD through multicenter, translational, research approaches and provide a central platform.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Atrial fibrillation screening-reading the P-wave]. [心房颤动筛查-阅读p波]。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-02 DOI: 10.1007/s00108-026-02193-3

Felix Wiedmann, Frederike Marie Weitkamp, Constanze Schmidt

{"title":"[Atrial fibrillation screening-reading the P-wave].","authors":"Felix Wiedmann, Frederike Marie Weitkamp, Constanze Schmidt","doi":"10.1007/s00108-026-02193-3","DOIUrl":"https://doi.org/10.1007/s00108-026-02193-3","url":null,"abstract":"Background: Atrial fibrillation (AF) is frequently intermittent and may therefore remain undetected on a short resting electrocardiogram (ECG). At the same time, a sinus-rhythm ECG contains information on the underlying atrial substrate.Objective: To review conventional and artificial intelligence (AI)-based ECG markers of an atrial risk phenotype and their potential role in targeted AF screening.Materials and methods: Narrative appraisal of current consensus and guideline documents and of clinical, electrophysiological, and population-based studies on P‑wave parameters, AI-ECG, and risk-adapted AF screening.Results: P‑wave duration, interatrial block, P‑wave terminal force in V1, and other parameters are associated with atrial remodelling and future AF. AI models additionally extract high-dimensional patterns from sinus-rhythm ECGs and can predict occult or future AF. Initial prospective data indicate that such risk signals can enrich the diagnostic yield of prolonged rhythm monitoring.Conclusion: The most plausible current clinical application is risk-adapted selection for prolonged rhythm monitoring. A P-wave or AI-based risk score neither establishes a diagnosis of AF nor, by itself, constitutes an indication for treatment.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Springer CME-Award 2025: Ambulant erworbene bakterielle Meningitis des Erwachsenen : Dr. med. Marie Madlener und Dr. med. Insa Joost werden für den besten Fortbildungsbeitrag ausgezeichnet. 施普林格CME奖2025：门诊获得性成人细菌性脑膜炎：医学博士。玛丽·麦德龙和医学博士。Insa Joost获得了最佳培训贡献奖。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-01 DOI: 10.1007/s00108-026-02168-4

M Holzem

引用次数: 0

[Digitalis for heart failure: welcome back?] 洋地黄治疗心力衰竭：欢迎回来？］

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-01 Epub Date: 2026-07-28 DOI: 10.1007/s00108-026-02156-8

Udo Bavendiek, Johann Bauersachs

{"title":"[Digitalis for heart failure: welcome back?]","authors":"Udo Bavendiek, Johann Bauersachs","doi":"10.1007/s00108-026-02156-8","DOIUrl":"10.1007/s00108-026-02156-8","url":null,"abstract":"Background: The use of cardiac glycosides (digitalis) for the treatment of heart failure with reduced ejection fraction (HFrEF) has steadily declined in the era of modern prognosis-improving pharmacotherapy, given the lack of conclusive evidence from clinical trials.Objectives: The evidence for the use of cardiac glycosides in HFrEF is presented based on both earlier and recent clinical trials, with corresponding recommendations.Current data: The recently published DIGIT-HF trial demonstrated that low-dose digitoxin (serum concentrations of 8-18 ng/ml) reduced the primary outcome of all-cause death and heart failure hospitalizations in patients with symptomatic HFrEF well treated with guideline-recommended medical therapy. Patients with low blood pressure and higher heart rates appeared to derive particular benefit. This positive treatment effect was independent of age and sex as well as the presence of atrial fibrillation or impaired renal function. In contrast, digoxin did not significantly affect the primary outcomes in the earlier DIG or the recently completed DECISION trial, the latter involving low-dose digoxin and contemporary heart failure pharmacotherapy. Both trials demonstrated nominally favorable effects for digoxin on heart failure hospitalizations/visits (secondary outcome), which was further supported by a meta-analysis incorporating data from all three trials.Conclusions: Digitoxin (at low serum concentrations) is recommended for patients with HFrEF and persistent symptoms despite standard therapy, since, in contrast to digoxin, there are positive trial data demonstrating a reduction in mortality and heart failure hospitalizations.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"1131-1136"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetes mellitus – neue Entwicklungen in der Diabetologie. 糖尿病：糖尿病学的新发展。

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1007/s00108-026-02186-2

Martin Reincke, Dagmar Führer-Sakel

引用次数: 0

[Immunotherapy and cell therapy in type 1 diabetes : Current state of research]. 1型糖尿病的免疫治疗和细胞治疗：研究现状

IF 0.6

Innere Medizin (Heidelberg, Germany) Pub Date : 2026-10-01 Epub Date: 2026-07-28 DOI: 10.1007/s00108-026-02167-5

Sarah Schill, Lena Schwenker, Franziska Reinmüller, Peter Achenbach, Anette-G Ziegler

{"title":"[Immunotherapy and cell therapy in type 1 diabetes : Current state of research].","authors":"Sarah Schill, Lena Schwenker, Franziska Reinmüller, Peter Achenbach, Anette-G Ziegler","doi":"10.1007/s00108-026-02167-5","DOIUrl":"10.1007/s00108-026-02167-5","url":null,"abstract":"Background: Type 1 diabetes begins as an autoimmune disease and can already be diagnosed in the presymptomatic early stage by detecting at least two positive islet autoantibodies (stage 1, International Classification of Diseases, 10th Revision, German Modification [ICD-10-GM]: R76.80; stage 2, ICD-10-GM: R73.00). Immunomodulatory therapies can slow disease progression and delay the clinical manifestation of type 1 diabetes. In parallel, cell therapy for β‑cell replacement is gaining increasing importance as a strategy to restore endogenous insulin production.Objectives: This article provides an overview of the current status of immunotherapies and cell therapies in type 1 diabetes.Materials and methods: The review \"The future of type 1 diabetes therapy\" by Ziegler et al. (2025) served as the basis. In addition, current guidelines, original articles, and selected studies on immunotherapies and β‑cell replacement therapies were considered.Results: With teplizumab, the first disease-modifying therapy for stage 2 type 1 diabetes is available. It delays the transition to clinically manifest type 1 diabetes (stage 3) by an average of 2-3 years. Other immunomodulatory therapeutic approaches show preservation of residual β‑cell function in stage 3 type 1 diabetes but are not yet approved for this indication. Stem-cell-based β‑cell replacement therapies are currently being clinically investigated in people with advanced diabetes and impaired awareness of hypoglycemia.Conclusion: Immunotherapies and cell therapies mark a paradigm shift in the treatment of type 1 diabetes. In the future, combination therapies will be particularly important to improve the durability of therapeutic effects, as will strategies to protect transplanted cells from alloimmunity and autoimmunity.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"1055-1062"},"PeriodicalIF":0.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0